A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Start Date
12/3/2025
Completion Date
1/1/2028
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Praliciguat
Placebo
Conditions
Locations
Investigator Site #2
Chula Vista, California 91910
United States
Investigator Site #14
Los Angeles, California 90022
United States
Investigator Site #12
San Dimas, California 91773
United States
Investigator Site #13
Arvada, Colorado 80002
United States
Investigator Site #17
Boca Raton, Florida 33431
United States
Investigator Site #6
Coral Springs, Florida 33071
United States
Investigator Site #7
Miami, Florida 33172
United States
Investigator Site #8
Orlando, Florida 32806
United States
Investigator Site # 1
Lawrenceville, Georgia 30046
United States
Investigator Site #3
Chicago, Illinois 60643
United States
Investigator Site #11
Louisville, Kentucky 40205
United States
Investigator Site #15
Livonia, Michigan 48152
United States
Investigator Site #10
Pontiac, Michigan 48341
United States
Investigator Site #16
New Bern, North Carolina 28562
United States
Investigator Site #20
Cleveland, Ohio 44106
United States
Investigator Site #19
Bridgeville, Pennsylvania 15017
United States
Investigator Site #22
Butler, Pennsylvania 16001
United States
Investigator Site #23
Goose Creek, South Carolina 29445
United States
Investigator Site #4
Chattanooga, Tennessee 37404
United States
Investigator Site #5
Arlington, Texas 76015
United States
Investigator Site #21
Dallas, Texas 75230
United States
Investigator Site #9
Dallas, Texas 75231
United States
Investigator Site #18
Houston, Texas 48152
United States